StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine,
“Regeneration-Inducing Medicine™”.
March 15, 2024 | Financial Results Presentation Materials | Presentation Materials for Six Months Ended January 31, 2024 |
---|---|---|
March 13, 2024 | Financial Results | Non-consolidated Financial Results for the Six Months Ended January 31, 2024[Japanese GAAP] |
March 13, 2024 | Timely Disclosure Information | StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy |
February 29, 2024 | Timely Disclosure Information | StemRIM Announces Fixed Details of the Issuance of Stock Options to External Collaborators |
February 15, 2024 | Timely Disclosure Information | StemRIM Announces Patent Registration (Japan) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication of Traumatic Cartilage Deficiency Syndrome, Osteoarthritis, and Disseverance Osteochondritis |
April 25, 2023 | NEWS Release |
---|
StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine, “Regeneration-Inducing Medicine™”.
“Regeneration-Inducing Medicine™” is an innovative new class of medicine that induces functional regeneration of tissues and organs in the patient's body by maximizing the human body's innate ability of tissue repairing.
We are pursuing research and development of new drugs based on a novel mechanism of action leading to recruitment of the patients’ own in-vivo stem cells to the damaged tissues for functional tissue regeneration without conventional cell-therapy approaches.